English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Breast cancer in women, and especially in young women, represents a real public health issue given its frequency and severity. The objective of our study is to specify the epidemiological profile; anatomo-clinical; therapy and prognosis of breast cancer in young women. Methods: Descriptive retrospective study spread over a period of 5 years (2013-2017), collecting all the patients followed for breast cancer aged 40 years or less, within the cancer department of CHU Med VI in Marrakech. Results: The average age was 34.2 years (19-40 years). The average age at puberty was 12 years old (9 and 16 years old). Nulliparity was noted in 22% of the cases. Clinically, the T classification in the cases specified was: T1 (n = 48), T2 (n = 128), T3 (n = 52), T4 (n = 42). Clinical lymph node involvement was found in 44% of the cases. Histologically, infiltrating ductal carcinoma was the most common (n = 283). SBR II grade was the most frequent with a rate of 66%, Thirty Fifty percent of all patients had an over-expression of HER2 , Sixtythree percent had lymph node invasion, including 42% with capsular rupture and 31% of patients were metastatic in appearance. Therapeutically, fifty patients had neo-adjuvant chemotherapy. The surgery was conservative in 66% of the cases. Adjuvant chemotherapy was sequential in 61% of the cases. 180 patients had adjuvant radiation therapy. Of the 96 patients with HER2 over expression, 82 received treatment with trastuzumab. Hormone therapy was prescribed in 156 patients or 49% of cases with expression of hormone receptors. In our series, the median follow-up was 8.1 months. The course was marked by a locoregional relapse in fifty-eight patients, and a metastatic relapse in sixty patients. Conclusion: Since screening in our country does not include young women, it would be interesting to reconsider its indications, especially given the growing frequency of this cancer in young women as well as its poor prognosis.

scholars international journal of obstetrics and gynecology

Breast Cancer in Young Women under 40 years: Epidemiological, Clinical, Therapeutic and Prognostic Aspects in the Oncology and Radiotherapy Department of Marrakech; About 318 Cases